NBY

NioBay Metals to Participate in THE Mining Investment Event of the North, Canada's Only Tier I Global Mining Investment Conference

Retrieved on: 
星期四, 五月 30, 2024
NBY, Mining

Montreal, Quebec--(Newsfile Corp. - May 30, 2024) - NioBay Metals (TSXV: NBY) (OTCQB: NBYCF) is pleased to announce that it will be participating in THE Mining Investment Event of the North, (“THE Event”) taking place June 4-6, 2024 in Quebec City at the Centre des congrès de Québec.

Key Points: 
  • Montreal, Quebec--(Newsfile Corp. - May 30, 2024) - NioBay Metals (TSXV: NBY) (OTCQB: NBYCF) is pleased to announce that it will be participating in THE Mining Investment Event of the North, (“THE Event”) taking place June 4-6, 2024 in Quebec City at the Centre des congrès de Québec.
  • Management from NioBay Metals will be holding one-on-one investor meetings throughout the three-day conference.
  • Investors are invited to contact Jennifer Choi at [email protected] to inquire about registering to attend.

NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates

Retrieved on: 
星期三, 五月 29, 2024
Biotechnology, Pharmaceutical, Optical, Health, Security (finance), CUSIP, Exercise, Computershare, Shareholder, Bank statement, NBY, Annual report

Among the proposals, stockholders approved a reverse stock split and authorized the Company’s Board of Directors to determine the specific split ratio and effective date.

Key Points: 
  • Among the proposals, stockholders approved a reverse stock split and authorized the Company’s Board of Directors to determine the specific split ratio and effective date.
  • “We thank stockholders for their support in approving all proposals during our annual meeting,” said Justin Hall, NovaBay’s CEO.
  • The effect of the reverse stock split will be to combine every 35 shares of outstanding Company common stock into 1 share of common stock.
  • The reverse stock split will not modify any voting rights or other terms of the common stock.

NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms

Retrieved on: 
星期一, 五月 13, 2024
Biotechnology, Health, Pharmaceutical, Optical, Medical Supplies, Chek, Patient, Telecanthus, Eye, Hygiene, Prevalence, Specialization, NBY, Hypochlorous acid, Demodex, Cosmetics

The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.

Key Points: 
  • The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.
  • “Our new Avenova product bundles align with where we see the market going, as confirmed by the 2024 Dry Eye Report.
  • In addition to Avenova spray, the Avenova over-the-counter product line includes the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health.
  • The 2024 Dry Eye Report surveyed 337 optometrists across the U.S., with the majority as primary eye care and dry eye specialists.

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Online Retail, Health, Cosmetics, Retail, Amazon (company), NBY, Record, Research and development, Marketing, ID, G&A, Growth, Pharmaceutical industry

(NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.

Key Points: 
  • (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.
  • Research & development (R&D) expenses for the first quarter of 2024 were $19 thousand, versus $10 thousand for the prior-year period.
  • Other expense, net for the first quarter of 2024 was $0.5 million, primarily due to the issuance of the March 2024 warrant and the unsecured convertible notes issued in March 2024, with no comparable item in the first quarter of 2023.
  • NovaBay had cash and cash equivalents of $1.8 million as of March 31, 2024, compared with $2.9 million as of December 31, 2023.

NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon

Retrieved on: 
星期二, 五月 7, 2024
Biotechnology, Online Retail, Health, Cosmetics, Retail, Chek, Amazon (company), Marketing, Telecanthus, Growth, NBY

(NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel.

Key Points: 
  • (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel.
  • “We are very excited about our progress with ordered product sales for Avenova on Amazon, including setting a record for ordered product sales in March and then immediately beating that record in April.
  • Ordered product sales in the previous two months have even eclipsed prior months that included record sales days during Prime Day events,” said Justin Hall, CEO of NovaBay.
  • We attribute these unparalleled sales months to the high quality of our Avenova products and the effectiveness of those cost-efficient marketing programs.

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

Retrieved on: 
星期五, 五月 3, 2024
Cosmetics, Retail, Health, Pharmaceutical, Optical, Biotechnology, ID, Webcast, NBY

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Key Points: 
  • NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
  • Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator.
  • Those who choose not to pre-register can access the live conference call by dialing the following and requesting conference call ID# 85516:
    888-500-3691 from within the U.S.
    646-307-1951 from outside the U.S.
  • The live webcast of the conference call also will be available on the Events section of the Company website.

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales

Retrieved on: 
星期一, 四月 22, 2024
Online Retail, Pharmaceutical, Family, Optical, Consumer, Retail, Marketing, Women, Biotechnology, Communications, Medical Supplies, Health, SMS, Automation, News, Social media, NBY, Mobile phone

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products.

Key Points: 
  • NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products.
  • The new and enhanced programs build upon the Company’s past highly productive marketing programs through proprietary channels including social media and email to cost-efficiently enhance customer loyalty and reach new prospective customers.
  • “SMS provides an additional, immediate touchpoint with our customers and we are encouraged by the strong initial results.
  • “The new SMS program builds on the incredible success we’ve had with our email and social media marketing programs to date,” he added.

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity

Retrieved on: 
星期五, 四月 19, 2024
Pharmaceutical, Health, Optical, Security (finance), NBY

(NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity.

Key Points: 
  • (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity.
  • The Company intends to submit a plan to regain compliance to the NYSE American within the prescribed timeframe.
  • The notice from the NYSE American has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on the NYSE American.
  • The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission (SEC).

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

Retrieved on: 
星期三, 四月 17, 2024
Communications, Health, Social Media, Pharmaceutical, Optical, Biotechnology, Social media, Pinterest, NBY, Optometry, Ophthalmology, Marketing, Beauty, Knowledge

(NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023.

Key Points: 
  • (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023.
  • This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
  • “We started 2024 with strong revenue growth from our core eyecare business while reducing marketing spend by capitalizing on our e-marketing expertise,” said Justin Hall, CEO of NovaBay.
  • “Investing in direct-to-consumer marketing to leverage our clinical pedigree is a modern approach to the pharmaceutical industry’s traditional sales model.

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Retrieved on: 
星期三, 三月 13, 2024
Clobetasol, NBY, Physician, Inflammation, Patient, Food and Drug Administration, NovaBay Pharmaceuticals, Pain, FDA, Ophthalmology, Food, Pharmaceutical industry

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.

Key Points: 
  • EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
  • Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
  • Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023.
  • This co-promotion agreement reflects our shared commitment to bring scientifically developed, cutting-edge and high-quality ophthalmic products to physicians and the patients they treat.”